Dr. Xu has served on ThermoGenesis Holdings’ board of directors since March 2016, and was appointed chairman and chief executive officer since November 2016. He brings over 15 years of leadership experience in the biopharmaceutical industry and has contributed to numerous successful product launches. In 2009, Dr. Xu founded Boyalife Group, a global diversified life sciences holding company and is currently the principal shareholder of ThermoGenesis Holdings. Prior to founding Boyalife, Dr. Xu served as a project leader at Pfizer, as a director of research at two publicly traded companies and as a vice president at Founder Group. Dr. Xu’s expertise spans several diverse therapeutic areas, including arthritis & inflammation, cardiovascular disease, autoimmunity, oncology, and diabetes. He has authored over forty publications and has been recognized by a number of professional societies for his contributions to biomedical research. Dr. Xu received his Ph.D. in immunology from Washington University School of Medicine (St. Louis, USA) and an executive MBA from Emory University (Atlanta, USA).